Seoul National University Bundang Hospital
Seongnam-si, Kyung-gi, South Korea
NCT Number: NCT02145104
The purpose of this study is to evaluate of efficacy and safety of cilinidipine plus valsartan and valsartan alone in patients with essential hypertension inadequately controlled on valsartan monotherapy
Looking for future studies?
Notify Me20 year–75 year
All sexes
Interventional
Phase 3
Seongnam-si, Kyung-gi, South Korea
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 8 weeks
Time frame: 4 weeks
Time frame: 4, 8 weeks
IlDong Pharmaceutical Co Ltd
Industry
Comparison of the Efficacy and Safety of Cilnidipine 10mg/Valsartan 160mg Combination Therapy, Cilnidipine 5mg/Valsartan 160mg Combination Therapy and Valsartan 160mg Monotherapy in Hypertensive Patients Inadequately Controlled With Valsartan 160mg Monotherapy: a Multicenter, Randomized, Double Blind Phase III Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02692846
Aortic Stenosis, Supravalvular, Aortic Valve Disease
Bethesda, Maryland, United States
View Trial DetailsNCT00837122
Cardiovascular Diseases, Diabetes
Accra, Ghana
View Trial DetailsNCT06845007
Cardiovascular Diseases, Hypertension
Lisbon, Lisbon District, Portugal
View Trial DetailsNCT07762456
Behavior, Cardiovascular Diseases
Izmir, Turkey (Türkiye)
View Trial Details